Bio Platforms

EXCLUSIVE ONLINE CONTENT

3/7/2019

Biogen Announces Agreement to Acquire Nightstar Therapeutics

Biogen recently announced it has entered into an agreement to acquire Nightstar Therapeutics, a clinical-stage gene therapy company based in London, United Kingdom, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders.